Annovis Bio, Inc.

What they do

Annovis Bio develops buntanetap, a synthetically produced, orally administered, brain-penetrant small molecule designed to inhibit synthesis of neurotoxic proteins including APP, tau, alpha-synuclein and TDP43. The company is running a FDA-cleared pivotal Phase 3 trial in early Alzheimer's disease (NCT06709014) and an open-label extension study in Parkinson's disease (NCT07284784), and plans a third study in Parkinson's disease dementia contingent on funding. It has concluded 12 clinical studies to date, most in healthy volunteers, plus Phase 1/2 studies in early AD and PD patients. The company has no product revenue and funds operations through financings.

Revenue drivers

• No commercial revenue — The company reported $0.00 revenue in 2021, 2022, 2023, 2024 and 2025, and $0.00 in the quarter ended 2026-03-31; all income historically has come from financing, not product sales.
• Buntanetap in early Alzheimer's disease — The lead potential value driver is the pivotal Phase 3 AD trial; if the 6-month symptomatic portion supports an NDA, the company says a filing could come potentially within one year of that period's completion, but no product revenue exists today.
• Buntanetap in Parkinson's disease and PDD — The PD open-label extension is intended to help meet FDA patient exposure requirements for a future NDA, and a Parkinson's disease dementia protocol is being refined pending additional funding.

Recent performance

The company reported no revenue for the quarter ended June 30, 2026. Research and development expenses were $12.0 million for the three months ended June 30, 2026, versus $5.2 million a year earlier, while general and administrative expenses were $2.4 million versus $1.1 million. Cash and cash equivalents totaled $18.7 million as of June 30, 2026, down from $19.5 million at December 31, 2025, with 42.6 million shares outstanding. The balance sheet at June 30, 2026 showed total assets of $22.0 million, total liabilities of $26.3 million and shareholder equity of negative $4.3 million. Net loss was $28.9 million for 2025 and operating cash flow was negative $25.6 million for 2025.

Strategy

Annovis is prioritizing execution of the fully enrolled pivotal Phase 3 AD trial, which management says has 850 patients versus an original target of 760, with a 6-month database lock and top-line symptomatic readout planned for Q1 2027. It plans an AD open-label extension starting October 2026 for patients from both trial arms and prior AD trials, and the PD OLE has enrolled 266 of an estimated 500 patients across 26 activated U.S. sites. The company is refining a PDD protocol and says it will initiate that study contingent on additional funding. Management states it is preparing for regulatory submission and promoted Cheng Fang to Chief Scientific Officer to oversee clinical execution. To fund these programs it says it plans to explore equity and debt financings, strategic partnerships and other transactions.

Risks

• Going concern and funding need — Management concluded in the 10-K that substantial doubt exists about the company's ability to continue as a going concern for twelve months from the financial statement date, with cash of $19.5 million at December 31, 2025 expected to fund operations only into the third quarter of 2026 and the auditor's opinion containing an explanatory going-concern paragraph.
• Clinical and regulatory failure risk — The company has no approved product and its value depends on the Phase 3 AD trial, where the 6-month symptomatic portion would need to be well-designed and well-executed to potentially support an NDA, and on the PD OLE and planned PDD study.
• No revenue and recurring losses — Revenue has been $0.00 every year from 2021 through 2025, net loss was $28.9 million in 2025, and operating cash flow was negative $25.6 million in 2025, so operations depend on external capital.
• Delay risk on stated timelines — The AD OLE start in October 2026, Q1 2027 AD top-line readout, Q4 2026 PD OLE full enrollment and the PDD study all depend on funding and trial execution, and management states the PDD study will begin only contingent on additional funding.

Outlook

Management says the pivotal Phase 3 AD trial is fully enrolled with 850 patients and plans a 6-month database lock with top-line symptomatic readout in Q1 2027, with disease-modifying data expected a year later. The AD open-label extension is expected to start in October 2026 and the PD OLE, with 266 of 500 patients enrolled, is projected to complete enrollment in Q4 2026. The company says it is preparing for regulatory submission and will host a corporate update webinar on September 2, 2026.